Callan Family Office’s Insmed INSM Stock Holding History

Callan Family Office’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,968	Closed	-$485K	–	1242
2026 Q1	$485K	Buy	2,968 +197	+7%	+$30.3K	0.01%	778
2025 Q4	$482K	Buy	+2,771	New	+$506K	0.01%	795

Other funds holding INSM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Callan Family Office's INSM Position: Q2 2026 in Review

Callan Family Office sold out of Insmed (INSM) in Q2 2026, closing a stake of 2,968 shares — an estimated $485K sold.

Callan Family Office first reported a position in INSM in Q4 2025 and held it in 2 quarters. The position peaked at $485K in Q1 2026. 667 funds tracked by Wall St. Rank hold INSM as of Q2 2026.

Callan Family Office reported no remaining Insmed position as of Q2 2026 after selling out during the quarter.
Callan Family Office sold 2,968 Insmed shares in Q2 2026, an estimated $485K.
Callan Family Office first reported a position in Insmed in Q4 2025 and held it in 2 quarters.
Callan Family Office's Insmed position peaked at $485K in Q1 2026.
667 funds tracked by Wall St. Rank held Insmed as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.